Pharmacyclics, Inc. (PCYC) Posts Q2 Loss of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Big Beat for Pharmacyclics' (PCYC) Imbruvica - Baird
August 1, 2014 7:18 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) following Q2 results with Imbruvica putting up a big beat.
"We believe the substantial top-line beat will result in broad increases in consensus estimates as well as a... More
WallachBeth Capital Upgrades Pharmacyclics (PCYC) to Buy
August 1, 2014 6:52 AM EDTWallachBeth Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Hold to Buy.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $120.44 yesterday.
... More